The FDA and DEA lack formal policies and clear, publicly understandable procedures for decisions about drug scheduling, according to Reason’s reporting on a Government Accountability Office report. The finding concerns the administrative process behind federal classifications that govern access to controlled substances.

The available account identifies a procedural problem at both agencies. It does not identify particular substances affected, specify which internal steps lack written policies or establish that any individual classification is legally invalid. It also provides no agency responses or details of the watchdog’s recommendations.

The Government Accountability Office is a federal watchdog that works for Congress. It examines how agencies operate and evaluates whether government activities meet legal requirements and stated objectives. Its reports can identify administrative weaknesses and recommend changes, but a GAO finding does not itself change a drug’s legal classification.

Drug scheduling takes place under the Controlled Substances Act, the federal law that establishes five categories of controlled substances. Those categories reflect factors including abuse potential, accepted medical use and the risk of dependence. Classification affects the rules for manufacturing, distributing, prescribing and studying a substance.

That statutory framework is separate from the question raised by the reporting: whether the agencies have sufficiently documented and transparent methods for carrying out their responsibilities. The existence of a governing law does not, by itself, describe every internal procedure used to reach a decision.

How federal drug scheduling works

The Drug Enforcement Administration administers the federal controlled-substance system within the Justice Department. The Food and Drug Administration, part of the Department of Health and Human Services, contributes scientific and medical assessments to the scheduling process.

Under the ordinary scheduling process, the DEA requests a scientific and medical evaluation and a scheduling recommendation from the health department. Federal law makes the department’s scientific and medical conclusions binding on the DEA in those areas. The agencies therefore have distinct responsibilities within a shared decision process.

Scheduling generally involves rulemaking, which includes public notice and an opportunity to comment. Federal law also provides special procedures, including temporary scheduling in certain circumstances. The reported absence of formal agency policies should therefore be distinguished from an absence of statutory requirements or public rulemaking mechanisms.

Schedule I covers substances classified as having a high potential for abuse and no currently accepted medical use in treatment in the United States. Schedule II also covers substances with high abuse potential, but recognizes accepted medical uses subject to restrictions. The remaining schedules apply progressively different criteria concerning abuse and dependence.

Scheduling is also separate from FDA approval of a medicine. Approval evaluates a particular drug product for specified uses; scheduling determines its treatment under controlled-substance law. A medicine can be FDA-approved while remaining subject to prescribing, storage and distribution controls because of its schedule.

What to watch

The next points to establish are which procedures the GAO examined, what changes it recommended and how the FDA and DEA responded. Reason’s reported finding alone does not establish whether either agency has adopted corrective measures or whether any specific scheduling decision will be reconsidered.